– UK, Cambridge – Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the appointments of Dr. Roger Dansey (M.D.) and Hervé Hoppenot to its Board of Directors.
About Dr. Roger Dansey
Dr. Roger Dansey serves on the Boards of Directors of Inovio Inc. and Ottimo Pharma. Previously, he was interim chief oncology officer and CDO of Pfizer Oncology. He also served as CMO and president of research and development at Seagen before Pfizer acquired the company.
Earlier in his career, he held senior leadership positions at Merck, Gilead Sciences, and Amgen. Dr. Roger Dansey played a key role in the development and approvals of numerous important cancer therapies, including Keytruda (pembrolizumab), Xgeva/Prolia (denosumab), Zydelig (idelalisib), Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), Tivdak (tisotumab vedotin), and Tukysa (tucatinib).
Dr. Roger Dansey holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa, and before joining industry, he was an associate professor of hematology/oncology at the Karmanos Cancer Institute in Detroit.
About Hervé Hoppenot
Hervé Hoppenot is an advisor to the CEO and serves on the Board of Directors of Incyte, after serving 11 years as the company’s chairman and CEO. Under his leadership, Incyte tripled the number of clinical candidates, established an international presence in 15 countries, and grew revenues from $350 million to $4.2 billion. He also serves on the Boards of Directors of Pierre Fabre Laboratories and N-Power Medicine.
Previously, Hervé Hoppenot served as president of Novartis Oncology, originally joining as CCO, overseeing the industry’s largest oncology pipeline. He started his career at Rhône Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including as VP of oncology and head of the U.S. oncology business unit.
Hervé Hoppenot holds a degree from ESSEC Business School in France.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle Drug Conjugate (BDC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BDC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radioconjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass.
For more: https://www.bicycletherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.